Why Moderna Stock Rose Today
Shares of Moderna (NASDAQ: MRNA) climbed 3% on Monday following reports that Food and Drug Administration officials are considering a new safety warning for Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.
The FDA plans to add a warning that Johnson & Johnson's vaccine has been linked in extremely rare cases to Guillain-Barre syndrome, according to The Washington Post. Roughly 100 cases of the autoimmune condition have been reported among the more than 12 million people who have received that vaccine. No similar link has been found to that illness for the Moderna or Pfizer vaccines.
Image source: Getty Images.
Source Fool.com
